Value of Remission in Patients with Rheumatoid Arthritis: A Targeted Review

• Published in: Advances in therapy Vol. 39; no. 1; pp. 75 - 93
• Main Authors: Ostor, Andrew J., Sawant, Ruta, Qi, Cynthia Z., Wu, Aozhou, Nagy, Orsolya, Betts, Keith A.
• Format: Journal Article
• Language: English
• Published: Cheshire Springer Healthcare 01.01.2022
• Subjects: Antirheumatic Agents; Arthritis, Rheumatoid - drug therapy; Cardiology; Cost-Benefit Analysis; Efficiency; Endocrinology; Health Care Costs; Humans; Internal Medicine; Medicine; Medicine & Public Health; Oncology; Patient Acceptance of Health Care; Pharmacology/Toxicology; Quality of Life; Review; Rheumatology; Economic benefit; Rheumatoid arthritis; Healthcare resource utilization; Remission; Treat-to-target; Indirect cost; Direct cost
• DOI: 10.1007/s12325-021-01946-w
• ISSN: 0741-238X

The treat-to-target strategy, which defines clinical remission as the primary therapeutic goal for rheumatoid arthritis (RA), is a widely recommended treatment approach in clinical guidelines. Achieving remission has been associated with improved clinical outcomes, quality of life, and productivity. These benefits are likely to translate to reduced economic burden in terms of lower healthcare costs and resource utilization. As such, a literature review was conducted to better understand the economic value of remission. Despite the large heterogeneity found in RA-related economic outcomes across studies, patients in remission consistently had lower direct medical and indirect costs, less healthcare resource utilization, and greater productivity compared to those without remission. Remission was associated with 19–52% savings in direct medical costs and 37–75% savings in indirect costs. The economic value of remission should thus be considered in economic analyses of RA therapies to inform treatment and reimbursement decisions.